BioSpace News Archive

Santhera Pharmaceuticals is pleased to note the launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in the United States by Catalyst Pharmaceuticals, Inc., the Company’s commercialization partner for North America.

Anocca AB and EmendoBio Inc. announced a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.

Sensorion announces that it is publishing its Full Year 2023 Financial Report, which has been filed with the Autorité des marchés financiers.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, reports full-year 2023 financial results and business update.

Zomedica Corp. announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave diagnostic platform to chemiluminescent immunoassay platforms currently broadly utilized by reference laboratories globally.

Microbix Biosystems Inc. announces that its funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic® urokinase, a biologic drug for dissolving blood clots.

Company to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT.

iSpecimen Inc. healthcare specimen providers, today reported its financial and operating results for the twelve-month period ended December 31, 2023.

Addex Therapeutics announced that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain.

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc. today announced an AAV9 production program agreement.